• EV-Based Targeted Protein Degradation for Inflammation

  2026-08-12

  The reference study establishes an extracellular vesicle-based targeted protein degradation platform that uses an autophagy-related degradation signal to remove extracellular proteins without relying on receptors on target cells. Its dual-targeting design degraded TNF-α and IL-1β and reduced inflammation in rat and goat models of intervertebral disc degeneration, providing a modular framework for multi-protein intervention.

• Firefly Luciferase mRNA: Assay Design for Delivery

  2026-08-11

  Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) can serve as more than a bright reporter: it is a practical tool for separating mRNA delivery, translation, and cell-state effects. This guide connects reporter assay design with recent engineered mRNA delivery research.

• Ruxolitinib, DRP1, and ATC Cell Death

  2026-08-10

  The 2024 Cell Death and Disease study identifies a previously unrecognized link between JAK1/2–STAT3 activity, DRP1-dependent mitochondrial fission, and coordinated apoptosis and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma. Its model provides a mechanistic framework for evaluating ruxolitinib as a preclinical ATC intervention while highlighting the need for careful pathway, cell-death, and mitochondrial readouts.

• Parathyroid hormone (1-34) (human) in Kidney Models

  2026-08-09

  Use this bioactive PTH (1-34) peptide fragment to connect receptor pharmacology with spatially organized kidney and bone experiments. The guide covers dose selection, assembloid workflows, calcium-sensitive readouts, and troubleshooting for reproducible PTH/PTHrP receptor signaling studies.

• Palomid 529: A Mechanistic Assay Roadmap for ESCC

  2026-08-08

  Palomid 529 (P529) offers a useful pharmacological lens for studying PI3K/Akt/mTOR signaling in esophageal squamous cell carcinoma. This article translates RCN2-driven metastasis and cisplatin resistance findings into experimentally testable assay strategies while defining what P529 can—and cannot—demonstrate.

• Annexin V-PE Reagent for CD38 CAR-T Studies

  2026-08-07

  Use Annexin V-PE Reagent to convert phosphatidylserine exposure into a rapid, measurable readout for CD38 CAR-T cytotoxicity, fratricide, and assay optimization. This workflow pairs structural binder engineering with early apoptosis marker detection by flow cytometry or fluorescence microscopy.

• Sulfo-NHS-LC-Biotin: Technical Protocols for Cell Surface Bi

  2026-08-07

  Sulfo-NHS-LC-Biotin enables efficient, irreversible biotin labeling of primary amines on cell surface proteins under aqueous conditions. It is specifically suited for workflows requiring stable, extracellular biotinylation and downstream capture or detection via streptavidin systems. This reagent is not appropriate for reversible or intracellular biotinylation protocols.

• GLT-1 Upregulation Mitigates TBI via CB1-CREB Pathway Inhibi

  2026-08-06

  This study elucidates how upregulation of GLT-1 in astrocytes counteracts neuronal apoptosis and cognitive dysfunction after traumatic brain injury (TBI) by inhibiting the CB1-CREB signaling pathway. The findings propose a mechanistic link between cannabinoid signaling and glutamate homeostasis, highlighting targets for neuroprotection in TBI.

• Thioredoxin System Regulates CHK1 Inhibitor Sensitivity in N

  2026-08-06

  This study identifies the thioredoxin system as a critical determinant of CHK1 inhibitor sensitivity in non-small cell lung cancer (NSCLC) by regulating ribonucleotide reductase activity and deoxynucleotide pools through redox mechanisms. These insights advance our understanding of redox pathway modulation in cancer therapy and highlight new combinatorial strategies to improve CHK1 inhibitor efficacy with reduced toxicity.

• Magneto-Piezoelectric Scaffolds Target JAK2-STAT3 in Bone De

  2026-08-05

  Wu et al. engineered magneto-piezoelectric nanoparticles integrated into 3D-printed scaffolds that disrupt biofilms and selectively activate oxidative phosphorylation in Icam1+ macrophages via JAK2-STAT3 signaling. This dual-function approach enhances infectious bone defect regeneration, bridging anti-infective and immunomodulatory biomaterials.

• N1-Methylpseudouridine: Shaping the Next Era of mRNA Transla

  2026-08-05

  This article delivers a mechanistic and strategic deep-dive into how N1-Methylpseudouridine empowers translational researchers to control mRNA translation, minimize immunogenicity, and pioneer next-generation mRNA therapeutics. With insights connecting translational regulation and mitochondrial metabolism, plus actionable guidance on effective experimental design, it advances the discourse beyond standard product pages and unlocks new horizons in synthetic biology.

• SB203580: Precision p38 MAPK Inhibition for Neuroinflammatio

  2026-08-04

  SB203580, a highly selective p38 MAPK inhibitor, empowers researchers to dissect inflammation, neuroprotection, and pain signaling with exceptional specificity. Its robust workflow compatibility and unique inhibition profile make it indispensable for advanced cellular and in vivo models targeting the p38 MAPK pathway.

• Shufeng Xingbi Therapy Modulates Immune Balance and Gut Flor

  2026-08-04

  This study investigates the effects of Shufeng Xingbi Therapy (SFXBT) on Th1/Th2 immune equilibrium and intestinal microbiota in an allergic rhinitis (AR) rat model. The findings reveal that SFXBT improves nasal inflammation, rebalances immune markers, and beneficially alters gut bacterial composition, offering a mechanistic basis for its therapeutic action in AR.

• DAPI Solution (1 mg/mL): Precision Nuclear Visualization in

  2026-08-03

  DAPI Solution (1 mg/mL) from APExBIO empowers researchers to achieve robust nuclear visualization, enabling precise apoptosis detection and viability assessment in fixed and apoptotic cells. This guide bridges recent advances in intervertebral disc degeneration research with actionable staining protocols, troubleshooting tactics, and practical tips for extracting high-fidelity data using fluorescence microscopy and flow cytometry.

• Translating IAP Antagonism: AT-406 (SM-406) in Cancer Resear

  2026-08-03

  This thought-leadership article explores the translational potential of AT-406 (SM-406), an orally bioavailable IAP antagonist, in overcoming apoptosis resistance in oncology. By diving into mechanistic insights, strategic experimental guidance, and the evolving competitive landscape, we provide translational researchers with actionable frameworks to accelerate apoptosis pathway activation and chemosensitization in cancer models.

447 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page